Anthera Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2017. For the quarter, the company's loss from operations was USD 7,914,000 compared to USD 16,600,000 a year ago. Net loss applicable to common stockholders was USD 6,307,000 or USD 0.58 per basic and diluted share compared to USD 25,285,000 or USD 4.85 per basic and diluted share a year ago. For the nine months, the company's loss from operations was USD 27,177,000 compared to USD 42,598,000 a year ago. Net loss applicable to common stockholders was USD 19,704,000 or USD 2.12 per basic and diluted share compared to USD 51,345,000 or USD 10.04 per basic and diluted share a year ago.